BSE filing, NSE: WELCURE. Summary written from the filing by ALFA Finder's alert engine.
Welcure Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹0.18
- Market cap
- ₹22.25 Cr
- Revenue (annual)
- ₹365.5 Cr
- Net profit (annual)
- ₹-5.49 Cr
- P/E (TTM)
- -1.3×Sector 45.9×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Welcure Drugs & Pharmaceuticals Ltd
All →Welcure Drugs & Pharmaceuticals Board Meeting Outcome
Welcure Drugs & Pharmaceuticals approved the closure of its Ahmedabad corporate office. Operations will continue uninterrupted with records transferred to the registered office.
Welcure Drugs & Pharmaceuticals Other Announcement
Welcure Drugs submitted its Annual Secretarial Compliance Report for FY2026 under Regulation 24A. The report confirms overall compliance while noting historical fines paid for earlier procedural delays.
Welcure Drugs & Pharmaceuticals Q4 FY26 Results: Net Loss of ₹49.9 Cr
Welcure Drugs & Pharmaceuticals Ltd reported a net loss of ₹49.9 Cr for Q4 FY26.
- Key figure
- Net loss ₹49.9 Cr
Welcure Drugs & Pharmaceuticals Financial Results
Welcure Drugs and Pharmaceuticals reported annual total income of ₹367.00 Crore for FY26. The Board approved audited results, showing a net annual loss of ₹5.49 Crore.
- Value
- ₹367.0 Cr
Welcure Drugs & Pharmaceuticals Debt & Borrowing
Welcure Drugs & Pharmaceuticals Ltd confirmed it does not meet SEBI's 'Large Corporate' criteria for the financial year ended March 31, 2026. Consequently, the company is exempt from mandatory incremental borrowing through debt securities. Its outstanding borrowings as of the reporting date were nil.
Welcure Drugs & Pharmaceuticals Other Announcement
Welcure Drugs & Pharmaceuticals Ltd submitted its Regulation 74(5) certificate for the quarter and year ended March 31, 2026. The registrar, Skyline Financial Services, confirmed that no physical share certificates were received for dematerialization during this period. This is a routine regulatory disclosure with no impact on business operations.
Other board meeting date announcements
All →Inducto Steel Board Meeting Date
Inducto Steel meets 6 November 2026 to consider unaudited standalone and consolidated Q2 results. This is an advance notice; no decisions yet.
Starlog Enterprises Board Meeting Date
Starlog Enterprises intimated a board meeting on 05 Nov 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 2026. The meeting date is proposed, so the results are not yet approved.
KBS India Board Meeting Date
KBS India Limited gave notice of a board meeting on 06 November 2026 to consider unaudited results for the quarter and half year ended 30 September 2026. Trading window stays closed until 48 hours after results are announced.
iStreet Network Board Meeting Date
iStreet Network meets 6 November 2026 to consider unaudited Q2 results and a possible interim dividend. Trading window closes from 1 October 2026.
Pyramid Technoplast Board Meeting Date
Pyramid Technoplast announced a board meeting on 6 November 2026 to consider unaudited September quarter results. Trading window closes from 1 October 2026.
Visaman Global Sales Board Meeting Date
Visaman Global Sales schedules a 13 November 2026 board meeting to consider half-yearly unaudited results. The trading window stays closed until 15 November 2026.